Vasomedical Awarded New Patent For Automatic Regulation Of Pressure During EECP(R) Therapy

Main Category: Cardiovascular / Cardiology
Article Date: 06 Feb 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Vasomedical, Inc. (OTC: VASO.OB), a world leader in the noninvasive treatment of cardiovascular diseases, today announced that the United States Patent and Trademark Office has issued a new patent to Vasomedical on January 1, 2008. This new patent, US 7,314,478 B2 is for technology that automatically controls and precisely maintains the inflation and deflation pressures within the cuffs during enhanced external counterpulsation therapy. The patent also provides for a method to automatically release all applied pressure to the atmosphere in the event of a system or power failure as a safety measure to avoid injury to the patient.

At the start of treatment, the therapist selects the optimal inflation pressure for the patient to comfortably receive effective therapy; the technology then fully controls and maintains, with accuracy, the proper inflation and deflation pressures throughout the treatment.

"Control and maintenance of optimal pressure during EECP® treatment is essential to the effectiveness of this therapy for the high percentage of patients that may have irregular or premature heart beats," remarked Dr. John Hui, president and chief executive officer of Vasomedical and inventor of the patent. "This patent is critical to our ability to produce a completely automatic EECP® therapeutic system which is capable of providing maximal safety and effectiveness to patients."

"Vasomedical has devoted substantial efforts in clinical studies to enable us to understand the important physiological parameters that guide us in the development of our EECP® systems." Dr. Hui continued to state, "The methods covered by this patent have been engineered into our current TS4 and Lumenair models. Vasomedical will continue to develop intellectual properties in its drive to produce the best quality products for the benefit of patients suffering from cardiovascular disease, further demonstrating Vasomedical's leadership position in the noninvasive treatment arena and its commitment to increase shareholder value."

About Vasomedical, Inc. and EECP® Therapy

Vasomedical, Inc. develops, manufactures and markets EECP® therapy systems to deliver its proprietary form of enhanced external counterpulsation therapy. EECP® therapy is a noninvasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen. Function of the endothelium, the inner lining of blood vessels throughout the body, is also improved, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, and improve exercise performance and quality of life for thousands of people worldwide. For more information visit http://www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "offers," "plans," "potential," and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Vasomedical, Inc.